- Home
- EAD vs YMAB Comparison
EAD vs YMAB Comparison
Compare EAD & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAD
- YMAB
- Stock Information
- Founded
- EAD 2003
- YMAB 2015
- Country
- EAD United States
- YMAB United States
- Employees
- EAD N/A
- YMAB N/A
- Industry
- EAD Finance/Investors Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EAD Finance
- YMAB Health Care
- Exchange
- EAD Nasdaq
- YMAB Nasdaq
- Market Cap
- EAD 419.0M
- YMAB 386.7M
- IPO Year
- EAD N/A
- YMAB 2018
- Fundamental
- Price
- EAD $7.08
- YMAB $8.61
- Analyst Decision
- EAD
- YMAB Buy
- Analyst Count
- EAD 0
- YMAB 10
- Target Price
- EAD N/A
- YMAB $13.91
- AVG Volume (30 Days)
- EAD 178.9K
- YMAB 874.6K
- Earning Date
- EAD 01-01-0001
- YMAB 11-07-2025
- Dividend Yield
- EAD 8.91%
- YMAB N/A
- EPS Growth
- EAD N/A
- YMAB N/A
- EPS
- EAD N/A
- YMAB N/A
- Revenue
- EAD N/A
- YMAB $85,385,000.00
- Revenue This Year
- EAD N/A
- YMAB N/A
- Revenue Next Year
- EAD N/A
- YMAB $13.97
- P/E Ratio
- EAD N/A
- YMAB N/A
- Revenue Growth
- EAD N/A
- YMAB N/A
- 52 Week Low
- EAD $5.69
- YMAB $3.55
- 52 Week High
- EAD $6.81
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- EAD 49.17
- YMAB 81.21
- Support Level
- EAD $7.07
- YMAB $8.50
- Resistance Level
- EAD $7.12
- YMAB $8.56
- Average True Range (ATR)
- EAD 0.03
- YMAB 0.02
- MACD
- EAD -0.01
- YMAB -0.12
- Stochastic Oscillator
- EAD 22.22
- YMAB 100.00
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.